News

New phase 2 study initiated to determine the potential of ALTO-203 as an antidepressant in patients with major depressive disorder and anhedonia.

What are the links between social psychiatry and the family therapy movement?

The atypical antipsychotic was approved for the acute treatment of schizophrenia in 2009.

Have you checked out the latest Translating Research Into Practice column? Let us know!

An example of a female leader…

The FDA has cleared the first prescription digital therapeutic for major depressive disorder, Rejoyn.

Vistagen has enrolled the first participant in the PALISADE-3 phase 3 trial of fasedienol for the treatment of social anxiety disorder.

Trying to predict the future: foolish or wise?

Write to us now to be part of our series focused on addiction and substance use disorders this month.

The experts weighed in on a wide variety of psychiatric issues for the March 2024 issue of Psychiatric Times.

From a promising new intervention for treatment-resistant depression to another look at the STAR*D controversy, here are highlights from the week in Psychiatric Times.

Our Mood Disorders Section Editor discusses the disorder in honor of World Bipolar Day.

Here are some updates from the world of psychiatry throughout the month of March.

“The heart of the matter.” Researchers investigated the risk of cardiovascular disease associated with long-term ADHD medication use.

What is new in research on bipolar disorder?

Here’s a look back at selections from our March content series on mood disorders.

"The diameter of the bomb was thirty centimeters and the diameter of its effective range about seven meters, with four dead and eleven wounded."

Tomorrow is National Doctors’ Day!

Our March CME reviews the principles and applications of invasive and noninvasive neuromodulation techniques for the treatment of mood disorders. Here are 5 key takeaways.

Palestinian children in the Gaza Strip experience complex continuous trauma.

Courageous leadership is relevant for any stage of an organization or individual patient encountering crisis and the choice of multiple options of how to proceed.

This treatment is now the first and only TMS treatment that is FDA-cleared for this patient population.

Here's why it's important to take your time...

The short-acting psychedelic, BPL-003, resulted in rapid, durable depression symptom reduction in patients with TRD.

What is the Clubhouse model of psychosocial rehabilitation, and how can it benefit both patients and clinicians alike?

Some of the most divisive notions in the Western world and the Global North: individualism and independence. Are they a myth?

Expiring on May 20, 2024, this CME discusses how to apply several novel treatment approaches in the treatment of patients with bipolar depression. Here are 5 key takeaways.

The treatment significantly reduced the frequency of cataplexy attacks in patients with narcolepsy compared with placebo.

The world would benefit from the values and knowledge of Indigenous individuals, who have been displaced and colonized.

“Our patients, our field, and our integrity demand a better explanation of what happened in STAR*D than what has thus been provided.”